Magenta Therapeutics stock forecast: up to 0.98 USD MGTA stock price prognosis


Forecast for Fri 04 Aug 2023 price 0.98

Magenta Therapeutics stock price forecast for further price development up to 35.45% (time horizon: 1 day) and price target of 0.98 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) Magenta Therapeutics share price prediction for 2023-08-04 with daily closed price projections

Key Facts

Symbol MGTA 

ISIN US55910K1088 

CUSIP 55910K108

Currency USD

Category Pharmaceutical Preparations

Forecast price change %

News sentiment (-0.24)

News <--> Close correlation for next day influence (0.08)

Finance numbers

Revenue 0.0

Earnings per share -1.71

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

In an autologous transplant, the patient's own stem cells are used. Arrows indicate timing and dose of the in vivo selection agent, O6BG/BCNU. Initial data from the study are expected in mid-2021. 8226; C300: targets only immune cells. &# 8226; G100: targets alloreactive T cells implicated in GvHD. This was comparable to historical data with multiple doses of busulfan conditioning. However, GvHD can occur even with proper matching. Bars represent median and each symbol represents an individual mouse (n=eight). Statistics were determined by a one-tailed Student's t-test. The Novartis Agreement led to the establishment of MGTA-456 as one of our programs. We refer to this agreement, as amended, as the Heidelberg Agreement. We may obtain such exclusive target-specific rights to up to four targets. 50 Table of Contents The FDA and the sponsor must reach an agreement on the PSP. The FDA will not approve the NDA or BLA without an approved REMS, if required. It is unclear what impact these rulings will have on our business. A separate application will, however, still be required. This final rule codified CMS's policy change that was effective January 1, 2019. It is unknown how long these pauses or disruptions could continue. &# As of December 31, 2020, we had an accumulated deficit of $254.4 million. We were founded and commenced operations in June 2015. We may not generate revenues from product sales for the next several years, if ever. In addition, ADCs may have other adverse side effects including fatalities. Heidelberg Pharma has filed an IND with the FDA that has been accepted. Designation as a breakthrough therapy is within the discretion of the FDA. For additional information regarding our competition, see "Item 1. As a result, we could lose our trade secrets. As a result, our revenue from applicable products could be reduced. Litigation may be necessary to defend against these claims. We cannot predict the success of any collaboration that we enter into. We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document.

Summerized Form 10-K with GPT-2
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 34.72/100
    • Good financial position.
    • Historical view, profit is not growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
A - B. Riley Wealth Advisors, Inc. 2022-12-31 28000
UMB Bank, n.a. 2022-12-31 742
Allworth Financial LP 2022-12-31 325
JANUS HENDERSON GROUP PLC 2022-09-30 3308899

Fund ownership list is based on filling form information

Fund name Date Amount Profile
JNL Series Trust 2022-12-31 12172 Long
iShares Trust 2022-12-31 20068 Long
iShares Trust 2022-12-31 91721 Long
John Hancock Variable Insurance Trust 2022-12-31 2418 Long
Blackstone Alternative Investment Funds 2022-12-31 3900 Long

Bollinger Bollinger Bands for Magenta Therapeutics can provide the information where the market is moving based on price information.

Magenta Therapeutics Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

Converting prices to returns Magenta Therapeutics.

On-Balance Volume information for Magenta Therapeutics. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for Magenta Therapeutics. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for Magenta Therapeutics. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for Magenta Therapeutics. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for Magenta Therapeutics. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for Magenta Therapeutics. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for Magenta Therapeutics. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

52W High 52W Low Market Cap

Similar shares

Magenta Therapeutics on Nasdaq

Magenta Therapeutics on finviz

Figure below show the stock predictions.
Date Closing price Prediction was updated
2023-08-04 0.98 2023-06-09 18:20
2023-07-31 0.95 2023-06-09 18:20
2023-08-01 0.96 2023-06-09 18:20
2023-08-02 0.96 2023-06-09 18:20
2023-08-03 0.97 2023-06-09 18:20
2023-06-12 0.72 2023-06-09 18:20
2023-06-13 0.73 2023-06-09 18:20
2023-06-14 0.74 2023-06-09 18:20
2023-06-19 0.77 2023-06-09 18:20
2023-06-20 0.77 2023-06-09 18:20
2023-06-16 0.76 2023-06-09 18:20
2023-06-15 0.74 2023-06-09 18:20
2023-06-21 0.78 2023-06-09 18:20
2023-06-22 0.79 2023-06-09 18:20
2023-06-23 0.79 2023-06-09 18:20
2023-06-26 0.80 2023-06-09 18:20
2023-06-27 0.80 2023-06-09 18:20
2023-06-28 0.81 2023-06-09 18:20
2023-06-29 0.82 2023-06-09 18:20
2023-06-30 0.82 2023-06-09 18:20
2023-07-03 0.83 2023-06-09 18:20
2023-07-04 0.84 2023-06-09 18:20
2023-07-05 0.84 2023-06-09 18:20
2023-07-06 0.85 2023-06-09 18:20
2023-07-07 0.86 2023-06-09 18:20
2023-07-10 0.86 2023-06-09 18:20
2023-07-11 0.87 2023-06-09 18:20
2023-07-12 0.87 2023-06-09 18:20
2023-07-13 0.88 2023-06-09 18:20
2023-07-14 0.89 2023-06-09 18:20
2023-07-17 0.89 2023-06-09 18:20
2023-07-18 0.90 2023-06-09 18:20
2023-07-19 0.90 2023-06-09 18:20
2023-07-20 0.91 2023-06-09 18:20
2023-07-21 0.92 2023-06-09 18:20
2023-07-24 0.92 2023-06-09 18:20
2023-07-25 0.93 2023-06-09 18:20
2023-07-26 0.93 2023-06-09 18:20
2023-07-27 0.94 2023-06-09 18:20
2023-07-28 0.95 2023-06-09 18:20

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.